Methods relating to DENND1A Variant 2 and polycystic ovary syndrome

A method for selecting an individual as a candidate for therapy for polycystic ovary syndrome, the method comprising the steps of:

• measuring an amount of DENND1A Variant 2 mRNA in a urine sample from said individual,
• wherein the amount of DENND1A Variant 2 mRNA is measured by hybridizing a labeled probe to the DENND1A Variant 2 mRNA or to DNA amplified from the DENND1A Variant 2 mRNA, and detecting the labeled probe hybridized to the DENND1A Variant 2 mRNA or detecting the labeled probe hybridized to amplified DNA,
• wherein said labeled probe hybridizes to a DENND1A Variant 2 mRNA or DNA sequence that is absent from DENND1A Variant 1 mRNA or DNA sequence;
• or
• wherein the amount of DENND1A Variant 2 mRNA is measured by detecting a signal from a fluorescently labeled nucleotide released from a probe hybridized to amplified DNA, wherein the fluorescently labeled nucleotide is released by exonuclease activity on the probe during amplification of the DENND1A Variant 2 mRNA into double stranded DNA,
• wherein said probe hybridizes to a DENND1A Variant 2 mRNA or DNA sequence that is absent from DENND1A Variant 1 mRNA or DNA sequence;
• comparing the amount of DENND1A Variant 2 mRNA to a reference value, and
• diagnosing said individual with polycystic ovary syndrome when said amount of DENND1A Variant 2 mRNA is increased as compared to the reference value, and
• designating the individual diagnosed with polycystic ovary syndrome as a candidate for the polycystic ovary syndrome therapy.